James Lucocq, Fraser Barbour, Kim Keltie, Edward O'Toole, Manu Nayar, Sanjay Pandanaboyana
{"title":"英格兰急性胰腺炎发病率、病因和死亡率的十年（2013-2023 年）分析。","authors":"James Lucocq, Fraser Barbour, Kim Keltie, Edward O'Toole, Manu Nayar, Sanjay Pandanaboyana","doi":"10.1016/j.hpb.2025.02.003","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the present study was to report epidemiological data on the incidence of acute pancreatitis (AP) in England between 2013 and 2023 and report contemporary post-AP outcomes.</p><p><strong>Methods: </strong>A search of patients admitted with AP (2013-2023) was performed within the Hospital Episode Statistics (HES) which covers all admitted patients within England using diagnosis (ICD-10) code K85.</p><p><strong>Results: </strong>A total of 260,009 patients (median age, 59 years; IQR, 30; F:M, 1.02:1) were identified from 185 NHS trusts (2013-2023), with an incidence of 456 cases per million and an annual increase of 2.6 %. A total of 8.0 % patients required ITU admission. The AP readmission rate was 30.2 % after a median follow-up time of 45 months (Q1-Q3, 17-80 months). The in-hospital mortality rate was 4.5 % (n = 11,711). The overall survival at 1, 2, 5 and 10 years was 88.9 [95%CI 88.7,89], 85.2 [85.1,85.4], 76.1 [75.9,76.3] and 63.9 [63.6,64.2]. Long-term survival (10-year) was higher with biliary aetiology (p < 0.01), younger age groups (p < 0.05) and those without ITU admission (p < 0.01).</p><p><strong>Conclusions: </strong>The incidence of AP in England is increasing and in-hospital mortality rates remain significant. These findings have implications for resource allocation to mitigate risk factors for developing AP in addition to the need for long-term follow-up for at-risk groups.</p><p><strong>Clinical trial registration: </strong>N/A.</p>","PeriodicalId":13229,"journal":{"name":"Hpb","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A 10-year (2013-2023) analysis of incidence, etiology and mortality of acute pancreatitis in England.\",\"authors\":\"James Lucocq, Fraser Barbour, Kim Keltie, Edward O'Toole, Manu Nayar, Sanjay Pandanaboyana\",\"doi\":\"10.1016/j.hpb.2025.02.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The aim of the present study was to report epidemiological data on the incidence of acute pancreatitis (AP) in England between 2013 and 2023 and report contemporary post-AP outcomes.</p><p><strong>Methods: </strong>A search of patients admitted with AP (2013-2023) was performed within the Hospital Episode Statistics (HES) which covers all admitted patients within England using diagnosis (ICD-10) code K85.</p><p><strong>Results: </strong>A total of 260,009 patients (median age, 59 years; IQR, 30; F:M, 1.02:1) were identified from 185 NHS trusts (2013-2023), with an incidence of 456 cases per million and an annual increase of 2.6 %. A total of 8.0 % patients required ITU admission. The AP readmission rate was 30.2 % after a median follow-up time of 45 months (Q1-Q3, 17-80 months). The in-hospital mortality rate was 4.5 % (n = 11,711). The overall survival at 1, 2, 5 and 10 years was 88.9 [95%CI 88.7,89], 85.2 [85.1,85.4], 76.1 [75.9,76.3] and 63.9 [63.6,64.2]. Long-term survival (10-year) was higher with biliary aetiology (p < 0.01), younger age groups (p < 0.05) and those without ITU admission (p < 0.01).</p><p><strong>Conclusions: </strong>The incidence of AP in England is increasing and in-hospital mortality rates remain significant. These findings have implications for resource allocation to mitigate risk factors for developing AP in addition to the need for long-term follow-up for at-risk groups.</p><p><strong>Clinical trial registration: </strong>N/A.</p>\",\"PeriodicalId\":13229,\"journal\":{\"name\":\"Hpb\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-02-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hpb\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.hpb.2025.02.003\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hpb","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hpb.2025.02.003","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
A 10-year (2013-2023) analysis of incidence, etiology and mortality of acute pancreatitis in England.
Introduction: The aim of the present study was to report epidemiological data on the incidence of acute pancreatitis (AP) in England between 2013 and 2023 and report contemporary post-AP outcomes.
Methods: A search of patients admitted with AP (2013-2023) was performed within the Hospital Episode Statistics (HES) which covers all admitted patients within England using diagnosis (ICD-10) code K85.
Results: A total of 260,009 patients (median age, 59 years; IQR, 30; F:M, 1.02:1) were identified from 185 NHS trusts (2013-2023), with an incidence of 456 cases per million and an annual increase of 2.6 %. A total of 8.0 % patients required ITU admission. The AP readmission rate was 30.2 % after a median follow-up time of 45 months (Q1-Q3, 17-80 months). The in-hospital mortality rate was 4.5 % (n = 11,711). The overall survival at 1, 2, 5 and 10 years was 88.9 [95%CI 88.7,89], 85.2 [85.1,85.4], 76.1 [75.9,76.3] and 63.9 [63.6,64.2]. Long-term survival (10-year) was higher with biliary aetiology (p < 0.01), younger age groups (p < 0.05) and those without ITU admission (p < 0.01).
Conclusions: The incidence of AP in England is increasing and in-hospital mortality rates remain significant. These findings have implications for resource allocation to mitigate risk factors for developing AP in addition to the need for long-term follow-up for at-risk groups.
期刊介绍：
HPB is an international forum for clinical, scientific and educational communication.
Twelve issues a year bring the reader leading articles, expert reviews, original articles, images, editorials, and reader correspondence encompassing all aspects of benign and malignant hepatobiliary disease and its management. HPB features relevant aspects of clinical and translational research and practice.
Specific areas of interest include HPB diseases encountered globally by clinical practitioners in this specialist field of gastrointestinal surgery. The journal addresses the challenges faced in the management of cancer involving the liver, biliary system and pancreas. While surgical oncology represents a large part of HPB practice, submission of manuscripts relating to liver and pancreas transplantation, the treatment of benign conditions such as acute and chronic pancreatitis, and those relating to hepatobiliary infection and inflammation are also welcomed. There will be a focus on developing a multidisciplinary approach to diagnosis and treatment with endoscopic and laparoscopic approaches, radiological interventions and surgical techniques being strongly represented. HPB welcomes submission of manuscripts in all these areas and in scientific focused research that has clear clinical relevance to HPB surgical practice.
HPB aims to help its readers - surgeons, physicians, radiologists and basic scientists - to develop their knowledge and practice. HPB will be of interest to specialists involved in the management of hepatobiliary and pancreatic disease however will also inform those working in related fields.
Abstracted and Indexed in:
MEDLINE®
EMBASE
PubMed
Science Citation Index Expanded
Academic Search (EBSCO)
HPB is owned by the International Hepato-Pancreato-Biliary Association (IHPBA) and is also the official Journal of the American Hepato-Pancreato-Biliary Association (AHPBA), the Asian-Pacific Hepato Pancreatic Biliary Association (A-PHPBA) and the European-African Hepato-Pancreatic Biliary Association (E-AHPBA).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
